International Conference on Machine Learning

NTT Research PHI Lab Scientists Address Bias in AI

Retrieved on: 
Tuesday, September 12, 2023
Other Professional Services, Software, Data Analytics, Internet, Artificial Intelligence, Professional Services, Technology, Other Technology, B.M.S. College of Engineering, Intelligence, Psychology, DNN, University, College, Phi Lab, Engineering, Harvard University, Linear optics, ICML, Stanford University, University of Cambridge, Ames Research Center, California Institute for Quantitative Biosciences, ML, Harvard Center for Population and Development Studies, Brain, Research, MIT, See, Conference on Neural Information Processing Systems, Associate, University of Notre Dame, Assistant, Science, Biology, International Conference on Learning Representations, Silicon, Tokyo Institute of Technology, Swinburne University of Technology, International Conference on Computer and Information Technology, Machine learning, CBFT, ICLR, International Conference on Machine Learning, Artificial intelligence, Paper, PHI, AI, NTT, Bias, Cornell University, Conference, Medical imaging, California Institute of Technology

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists affiliated with its Physics & Informatics (PHI) Lab have co-authored a paper that proposes a way to overcome bias in deep neural networks (DNNs).

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists affiliated with its Physics & Informatics (PHI) Lab have co-authored a paper that proposes a way to overcome bias in deep neural networks (DNNs).
  • “Our PHI Lab scientists and their colleagues have enlarged our understanding of the relatively neglected field of neural network fine-tuning in this notable paper and have proposed an innovative remedy for correcting against bias,” PHI Lab Director Yoshihisa Yamamoto said.
  • In a recent three-month span, top academic journals accepted or published a dozen papers co-authored by PHI Lab scientists.
  • The PHI Lab also has reached joint research agreements with numerous institutions, Harvard University being the most recent.

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Cloud, Clostridioides difficile infection, SALT, Chemistry, Development, CCM, Patient, ESG, SVP, DGX, Software, Partnership, Therapy, AXIN1, Drug discovery, Pharmacokinetics, Research, Genentech, International Conference on Information Systems Security and Privacy, Phenomics, Biology, Entrepreneurship, Real space, FDA, IND, Conference, Safety, Biotechnology, Toronto Office of Emergency Management, Roche, ML, Enamine, Administration, Generative, Ovarian cancer, NF2, International Conference on Machine Learning, Deep learning, Clinical trial, FAP, Proteomics, Trial of the century, Machine learning, Artificial intelligence, Wilson Sonsini Goodrich & Rosati, APC, Pharmaceutical industry, Cryptocurrency, Video game, Bayer, Cyclica, NVIDIA, Recursion

Revenue: Total revenue was $11.0 million for the second quarter of 2023, compared to $7.7 million for the second quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $11.0 million for the second quarter of 2023, compared to $7.7 million for the second quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $55.1 million for the second quarter of 2023, compared to $38.4 million for the second quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $28.3 million for the second quarter of 2023, compared to $21.2 million for the second quarter of 2022.
  • Net Loss: Net loss was $76.7 million for the second quarter of 2023, compared to a net loss of $65.6 million for the second quarter of 2022.

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

Retrieved on: 
Wednesday, July 26, 2023
ICML, ML, Research, SALT, Student, International Conference on Computational Intelligence Methods for Bioinformatics and Biostatistics, Machine learning, Drug discovery, Recursion, Biology, International Conference on Machine Learning, Artificial intelligence, Conference, Pharmaceutical industry

SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference on Machine Learning (ICML).

Key Points: 
  • SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference on Machine Learning (ICML).
  • Valence Labs will serve as a machine learning research laboratory focused on developing the next generation of cutting-edge methods and models for drug discovery and consists of the emerging ML research teams at Recursion and the team at Valence Discovery, which Recursion recently acquired.
  • "Recursion believes in the power of open-science initiatives and wants to invest in rising talent and academic collaborations.
  • We are also committed to upholding our legacy of contributing significant datasets and tools for research purposes," said Chris Gibson, Ph.D., Co-founder and CEO of Recursion.

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Retrieved on: 
Wednesday, June 14, 2023
AACR, ICML, CDK, Lymphoma, Bone marrow, Cancer, American Association for Cancer Research, Ribociclib, Patient, International Conference on Machine Learning, Mantle cell lymphoma, Chorioallantoic membrane, MCL, Poster, FDA, Therapy, Conference, Metastasis, Safety, Pharmaceutical industry

NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today presented preclinical data on narazaciclib at the 17th International Conference on Malignant Lymphoma (ICML), which is taking place in Lugano, Switzerland, through June 17, 2023.

Key Points: 
  • NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today presented preclinical data on narazaciclib at the 17th International Conference on Malignant Lymphoma (ICML), which is taking place in Lugano, Switzerland, through June 17, 2023.
  • Combining narazaciclib with the FDA-approved Bruton’s tyrosine kinase inhibitor ibrutinib led to synergistic increases in antitumor activity against both ibrutinib-sensitive and ibrutinib-resistant MCL cell lines.
  • The poster will also be displayed during the in-person poster sessions being held throughout the conference.
  • A copy of the poster will be available on the “ Scientific Presentations ” section of the Onconova website following the conclusion of the conference.

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

Retrieved on: 
Friday, June 9, 2023
STAT3, Peripheral T-cell lymphoma, PD, Cutaneous T-cell lymphoma, Follicular lymphoma, DLBCL, Relapse, ICML, Immunomodulatory imide drug, Lymphoma, Pharmacokinetics, Constipation, TPD, DL2, Abdominal pain, B-cell lymphoma, PBMC, Leukemia, Dizziness, Patient, International Conference on Machine Learning, Plasma, MYD88, Cancer, ABC, Nausea, Toxicity, Infrared spectroscopy correlation table, Therapy, Conference, Safety, Fatigue, Bone marrow, Vaccine, Pharmaceutical industry, Television, Risk management, Medical imaging, IRAK4, Black Majesty, Fever

WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate substantial target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The data were shared in the online abstract book of the International Conference on Malignant Lymphoma (ICML), taking place from June 13-17, 2023, in Lugano, Switzerland, and reflect a data cut-off date of February 3, 2023. On June 14, a KT-333 poster will be released at ICML and presented on June 16. Kymera will share updated results from both programs in conjunction with the poster release on June 14.

Key Points: 
  • Kymera will share updated results from both programs in conjunction with the poster release on June 14.
  • KT-333 is designed as a potent degrader of STAT3, a transcriptional regulator that has been linked to numerous cancers as well as to inflammatory and autoimmune diseases.
  • As previously announced, Kymera intends to present data evaluating anti-tumor activity in the target patient population later this year.
  • As previously announced, Kymera intends to present data evaluating anti-tumor activity in the target patient population later this year.

Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano

Retrieved on: 
Tuesday, May 30, 2023
Epstein–Barr virus, Nivolumab, ICML, Lymphoma, Malignancy, CHL, TT11, International Conference on Machine Learning, Patient, Poster, Therapy, CD30, ACTION, Conference, Bone marrow, Pharmaceutical industry

TT11, is Tessa’s autologous CD30.CAR-T therapy currently being investigated in combination with Nivolumab in a Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients.

Key Points: 
  • TT11, is Tessa’s autologous CD30.CAR-T therapy currently being investigated in combination with Nivolumab in a Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients.
  • A poster providing first peak into data from this combination study will be presented at ICML, 2023.
  • TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
  • Details of the two presentations are as follows:
    17th International Conference on Malignant Lymphoma, Lugano

Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma

Retrieved on: 
Tuesday, May 30, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Lymphoma, Bristol Myers Squibb, Abstract, Follicular lymphoma, ICML, Clinical trial, NHL, BMY, NYSE, CAR, International Conference on Machine Learning, Patient, Mantle cell lymphoma, Cell, MCL, Leukemia, Conference, Lisocabtagene maraleucel, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced the acceptance of two late-breaker abstracts for Breyanzi (lisocabtagene maraleucel) studies TRANSCEND FL and TRANSCEND NHL 001 for patients with relapsed or refractory follicular lymphoma (FL) and patients with relapsed or refractory mantle cell lymphoma (MCL), respectively, for presentation at the 2023 International Conference on Malignant Lymphoma (ICML).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the acceptance of two late-breaker abstracts for Breyanzi (lisocabtagene maraleucel) studies TRANSCEND FL and TRANSCEND NHL 001 for patients with relapsed or refractory follicular lymphoma (FL) and patients with relapsed or refractory mantle cell lymphoma (MCL), respectively, for presentation at the 2023 International Conference on Malignant Lymphoma (ICML).
  • These results follow the topline announcement shared on May 1 of this year.
  • “We are dedicated to bringing new and innovative treatment options to patients living with lymphoma and leukemia and believe that Breyanzi provides transformative potential for patients with heavily pre-treated relapsed or refractory follicular lymphoma or mantle cell lymphoma,” said Anne Kerber, senior vice president, head of Cell Therapy Development, Bristol Myers Squibb.
  • “TRANSCEND FL is the largest clinical trial to date evaluating CAR T cell therapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma, including follicular lymphoma.

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

Retrieved on: 
Wednesday, May 17, 2023
TCL, ICML, ITK, Lymphoma, Clinical trial, T-cell lymphoma, International Conference on Machine Learning, Patient, CEST, Biology, Poster, ACL, FDA, Conference, Safety, Pharmaceutical industry, Corvus

BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland.

Key Points: 
  • BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland.
  • “We look forward to presenting data at ICML supporting the biology and mechanism of immune enhancement resulting from selective ITK inhibition, along with the latest clinical data from our Phase 1/1b clinical trial of CPI-818 for T cell lymphoma.
  • CPI-818 is currently being studied in a Phase 1/1b clinical trial as a single agent therapy in patients with relapsed TCL.
  • Corvus recently incorporated a minimum absolute lymphocyte count (ACL) as an eligibility criterion for enrollment in the clinical trial.

AKASA Announces Accelerated Growth and Expanding Customer Base

Retrieved on: 
Tuesday, August 24, 2021
Center, Friends, Judgement, Automation, Machine learning, International Conference on Machine Learning, ICML, Heart, Mexican International Conference on Artificial Intelligence, AI, Machine, Health, Multimedia, Silicon, McIlroy, Partnership, SAN, Algorithm, Conference, Medicaid, Technology, Medical device

AKASA automates medical billing and claim remittances processes for healthcare providers that provide care across all 50 states.

Key Points: 
  • AKASA automates medical billing and claim remittances processes for healthcare providers that provide care across all 50 states.
  • "I was introduced to AKASA by friends in the healthcare world.
  • AKASA was also recently included in the Breakout List which features early-stage, high-growth companies that are particularly appealing to engineers and technical talent.
  • AKASA enables health systems to decrease their cost to collect so they can invest more in patient care and be better stewards of the healthcare dollar.

Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 12, 2021
Conference, Program, Infection, Immunity, Machine learning, S. aureus, Administration, GLOBE, MRSA, Coronavirus, Epitope, Vaccine, SARS-COV-2, Cancer, CEO, NASDAQ, PMHC cellular microarray, Skin, Webcast, Genetically modified bacteria, International Conference on Information Systems Security and Privacy, Staphylococcus aureus, IPO, Staphylococcus, Immune system, Research, Research and development, International Conference on Machine Learning, Development, CMC, EDT, Degenerative disease, Mass spectrometry, Adaptation, AI, Patient, Melanoma, Pharmaceutical industry, Cryptocurrency

Lars Wegner, CEO of Evaxion, said: Evaxion has made very encouraging clinical progress in the second quarter of 2021, reporting data in July which we believe support advancing both of our lead programs into Phase 2b trials.

Key Points: 
  • Lars Wegner, CEO of Evaxion, said: Evaxion has made very encouraging clinical progress in the second quarter of 2021, reporting data in July which we believe support advancing both of our lead programs into Phase 2b trials.
  • We plan to initiate a Phase 2b trial for EVX-01 in melanoma in December 2021 and initiate a Phase 2b trial of EVX-02, in conjunction with our third program, EVX-03, in Q2 2022.
  • Our cash reserves of $18.8 million provide a solid financial foundation and will facilitate the continued development of these four lead programs.
  • In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.